Skip to main content

Advertisement

SpringerLink
Log in

Significant prognostic factors in patients with Stage IV gastric cancer with special reference to the curability of surgery

  • Original Article
  • Published:
Surgery Today Aims and scope Submit manuscript

Abstract

Purposes

The purpose of this study was to determine an effective treatment strategy for patients with Stage IV gastric cancer.

Methods

We analyzed the significant prognostic factors in 74 patients who underwent surgery between 1989 and 2005, and were finally determined to have Stage IV gastric cancer. These patients were classified as curability A (n = 0), B (n = 29) and C (n = 45) according to the criteria outlined by Japanese Gastric cancer society. Anti-tumor drugs were used after surgery in some cases. There were 32 patients who received either no treatment or an oral anti-tumor drug, and 42 patients who received new chemotherapeutic regimens.

Results

According to a univariate analysis, the postoperative mean survival times were significantly different; tumor size ≤12 cm, a tumor without lymphatic involvement, more than D2 lymphadenectomy, and classification as curability B were favorable prognostic factors. The multivariate analysis revealed that tumor size, lymphadenectomy and curability were independent prognostic factors. In curability B patients, venous involvement was an independent prognostic factor. In curability C patients, both the tumor size and postoperative chemotherapy affected their prognosis.

Conclusions

In patients with curable Stage IV gastric cancer, at least a D2 gastrectomy to reduce the absolute volume of tumor cells, followed by adjuvant chemotherapy, may be essential to improve their prognosis. In incurable cases, aggressive new chemotherapeutic regimens should be the treatment of choice for the prolongation of survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Maehara Y, Kakeji Y, Takahashi I, Akazawa K, Sugimachi K. Time trends of surgical treatment and the prognosis for Japanese patients with gastric cancer. Br J Cancer. 2000;83:986–91.

    Article  PubMed  CAS  Google Scholar 

  2. Yagi Y, Seshimo A, Kameoka S. Prognostic factors in stage IV gastric cancer: univariate and multivariate analyses. Gastric Cancer. 2000;3:71–80.

    Article  PubMed  Google Scholar 

  3. Korenaga D, Tsujitani S, Haraguchi M, Okamura T, Tamada R, Sugimachi K, et al. Long-term survival in Japanese patients with far advanced carcinoma of the stomach. World J Surg. 1988;12:236–40.

    Article  PubMed  CAS  Google Scholar 

  4. Japanese Gastric Cancer Association. Gastric Cancer Treatment Guidelines (in Japanese). 3rd ed. Kanehara Shuppan: Tokyo; 2010.

  5. Masashi F, Mitsugu K, Tadatoshi T. Recent advances in chemotherapy for advance gastric cancer. Surg Today. 2010;40:295–300.

    Article  Google Scholar 

  6. Keishi Y, Shinichi S, Masahiko W. Genomic and epigenetic profiles of gastric cancer: potential diagnostic and therapeutic applications. Surg Today. 2011;41:24–38.

    Article  Google Scholar 

  7. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma (in Japanese). 13th ed. Kanehara shuppan, Tokyo; 1999.

  8. Saito H, Osaki T, Murakami T, Sakamoto T, Kanaji S, Oro S. Macroscopic tumor size as a simple prognostic indicator in patients with gastric cancer. Am J Surg. 2006;192:296–300.

    Article  PubMed  Google Scholar 

  9. Adachi Y, Oshiro T, Mori M, Maehara Y, Sugimachi K. Tumor size as a simple prognostic indicator for gastric carcinoma. Ann Surg Oncol. 1997;4:137–40.

    Article  PubMed  CAS  Google Scholar 

  10. Shiraishi N, Sato K, Yasuda K, Inomata M, Kitano S. Multivariate prognostic study on large gastric cancer. J Surg Oncol. 2007;1(96):8–14.

    Google Scholar 

  11. Baba H, Korenaga D, Haraguchi M, Okamura T, Saito A, Watanabe A, et al. Width of serosal invasion and prognosis in advanced human gastric cancer with special reference to the mode of tumor invasion. Cancer. 1989;64:2482–6.

    Article  PubMed  CAS  Google Scholar 

  12. Siewert JR, Boettcher K, Roder JD, Busch R, Hermanek P, Meyer HJ, German Gastric Carcinoma Study Group. Prognostic relevance of systematic lymph node dissection in gastric carcinoma. Br J Surg. 1993;80:1015–8.

    Article  PubMed  CAS  Google Scholar 

  13. Cuschieri A, Fayers P, Fielding J, Craven J, Bancewicz J, Joypaul V, Cook P. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. Lancet. 1996;347:995–9.

    Article  PubMed  CAS  Google Scholar 

  14. Baba H, Okuyama T, Hiroyuki O, Anai H, Korenaga D, Maehara Y, et al. Prognostic factors for noncurative gastric cancer: univariate and multivariate analysis. J Surg Oncol. 1992;51:104–8.

    Article  PubMed  CAS  Google Scholar 

  15. Wu CW, Hsiung CA, Lo SS, et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol. 2006;7:309–15.

    Article  PubMed  CAS  Google Scholar 

  16. Schwarz RE, Smith DD. Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage. Ann Surg Oncol. 2007;14:317–28.

    Article  PubMed  Google Scholar 

  17. Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359:453–62.

    Article  PubMed  CAS  Google Scholar 

  18. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–21.

    Article  PubMed  CAS  Google Scholar 

  19. Nashimoto A, Yabusaki H, Nakagawa S, Takii Y, Tsuchiya Y, Tanaka O. Preoperative chemotherapy with S-1 and cisplatin for highly advanced gastric cancer. Anticancer Res. 2009;29:4689–96.

    PubMed  CAS  Google Scholar 

  20. Nishiyama M, Wada S. Docetaxel: its role in current and future treatments for advanced gastric cancer—review article. Gastric Cancer. 2009;12:132–41.

    Article  PubMed  CAS  Google Scholar 

  21. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2008;357:1810–20.

    Article  Google Scholar 

  22. Fujii M, Kochi M, Takayama T. Recent advances in chemotherapy for advanced gastric cancer in Japan. Surg Today. 2010;40:295–300.

    Article  PubMed  CAS  Google Scholar 

  23. Maehara N, Hidaka H, Nagaike K, Nakashima S, Hotokezaka M, Chijiiwa K. Prognostic factors and usefulness of chemotherapy with S-1 in patients received gastrectomy for stage IV gastric cancer. Jpn J Cancer Chemother. 2009;36:1111–4. (in Japanese).

    Google Scholar 

  24. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol. 2003;1(21):54–9.

    Article  Google Scholar 

  25. Hanazaki K, Sodeyama H, Mochizuki Y, Igarashi J, Yokoyama S, Sode Y, et al. Palliative gastrectomy for advanced gastric cancer. Hepatogastroenterology. 2001;48:285–9.

    PubMed  CAS  Google Scholar 

  26. Hartgrink HH, Putter H, Klein Kranenbarg E, Bonenkamp JJ, van de Velde CJ. Value of palliative resection in gastric cancer. Br J Surg. 2002;89:1438–43.

    Article  PubMed  CAS  Google Scholar 

  27. Saidi RF, ReMine SG, Dudrick PS, Hanna NN. Is there a role for palliative gastrectomy in patients with stage IV gastric cancer? World J Surg. 2006;30:21–7.

    Article  PubMed  Google Scholar 

  28. Nakajima T, Ota K, Ishihara S, Oyama S, Nishi M, Ohashi Y, et al. Combined intensive chemotherapy and radical surgery for incurable gastric cancer. Ann Surg Oncol. 1997;4:203–8.

    Article  PubMed  CAS  Google Scholar 

  29. Gallardo-Rincon D, On˜ate-Ocan˜a LF, Calderillo-Ruiz G. Neoadjuvant chemotherapy with P-ELF (cisplatin, etoposide, leucovorin, 5-fluorouracil) followed by radical resection in patients with initially unresectable gastric adenocarcinoma. Ann Surg Oncol. 2000;7:45–50.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

Shinohara S and the co-authors have no conflict of interest to declare.

Author information

Authors and Affiliations

  1. Department of Surgery, Fukuoka City Hospital, 13-1 Yoshizuka-honmachi, Hakata-ku, Fukuoka, 812-0046, Japan

    Shinji Shinohara, Daisuke Korenaga, Ai Edagawa, Kenichi Koushi, Shinji Itoh, Hirofumi Kawanaka, Daihiko Eguchi, Katsumi Kawasaki, Toshiro Okuyama, Yasuharu Ikeda & Kenji Takenaka

Authors
  1. Shinji Shinohara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daisuke Korenaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ai Edagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kenichi Koushi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shinji Itoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hirofumi Kawanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Daihiko Eguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Katsumi Kawasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Toshiro Okuyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yasuharu Ikeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Kenji Takenaka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shinji Shinohara.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shinohara, S., Korenaga, D., Edagawa, A. et al. Significant prognostic factors in patients with Stage IV gastric cancer with special reference to the curability of surgery. Surg Today 43, 40–47 (2013). https://doi.org/10.1007/s00595-012-0230-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00595-012-0230-9

Keywords

Search

Navigation